MiMedx, Organogenesis Inc., Integra LifeSciences, ConvaTec Inc.and others are dominating the market for Australia, South Korea, India, Brazil, UAE and Iran wound care biologics market in 2017

Australia, South Korea, India, Brazil, UAE and Iran wound care biologics market is expected to register a healthy CAGR in the forecast period 2018 to 2025. The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Access Full Report: https://databridgemarketresearch.com/reports/customized-wound-care-biologics-market/

The Australia, South Korea, India, Brazil, UAE and Iran wound care biologics market is highly concentrated to a few big players and rest to local players who caters to domestic market only. MiMedx dominated the wound care biologics market accounting for a highest market share in 2017, followed by Organogenesis Inc., Integra Life Sciences and ConvaTec Inc. Other players in this market are Acell Inc., Allsource, Alphatec Spine, Inc., Amnio Technology, LLC, Amniox Medical, Inc., Anika Therapeutics, Inc., BioHorizons IPH, Inc., Kerecis, Marine Polymer Technologies, Inc., Mölnlycke Health Care AB, Osiris Therapeutics, Inc., Skye Biologics Inc., Smith & Nephew, Solsys Medical, Vericel Corporation, Wright Medical Group N.V. among others.

Anika Therapeutics, Inc:

Anika Therapeutics, Inc, founded in 1992 and headquartered in Massachusetts, U.S. focuses on Pain Management, tissue regeneration, wound healing. It operates its business through established Orthobiologics, Dermal, Surgical, Other HA solutions.It offers wound care biologics through its Orthobiologics, Surgical.

The company has its presence in United States, Europe and Others. It has its subsidiaries worldwide such as Anika Therapeutics,lnc. (Italy), Anika Securities Corp. (U.S.) and others.

  • In December 2017, Anika Therapeutics, Inc. (U.S.) received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for HA-based bone void filler The bone void filler, which is made up  of a synthetic, biocompatible bone graft substitute material

Smith and Nephew:

Smith and Nephew founded in 1856 and based in London, U.K. It is involved in designing, developing and selling of medical devices. It operates its business through Knee Implants, Advanced Wound Bioactives, Arthroscopic Enabling Technologies, Hip Implants, Advanced Wound Care, Sports Medicine Joint Repair, Advanced Wound Devices, Other Surgical Businesses, Trauma & Extremities. It offers wound care biologics   through its advanced wound care. The company has its presence in Asia Pacific, Europe, Middle East and Africa, America. It has its subsidiaries worldwide such as Blue Belt Technologies UK Limited (U.K.), Neotherix Limited (U.S.), Plus Orthopedics (U.K.) Limited (U.K.), Arthrocare Corporation (U.S.), Bioventus LLC (U.S.), Smith & Nephew Pty Limited (Australia), ArthoCare Medical Devices (Beijing) Co.Limited (China).

  • In 2008, the Advanced Wound Management division of Smith & Nephew launched new product to expand the ACTICOAT ACTICOAT Flex has been designed to give support physicians who deals with injuries at high risk of infection.

Osiris Therapeutics, Inc:

Osiris Therapeutics, Inc founded in 1992 and headquarters in Maryland, U.S., focuses manufacturing products for the research, development, manufacture and commercializing regenerative medicine.

 The company has its presence in U.S. It has its subsidiaries worldwide such as Osiris Therapeutics International GmbH (Switzerland)

  • In May 2008, Osiris Therapeutics, Inc. (COLUMBIA) received clearance by the U.S. Food and Drug Administration (FDA) for initiating an expanded access treatment program for prochymal by making the investigational stem cell product available to children with life-threatening Graft vs. Host Disease (GvHD).